Bavarian Nordic Reports the EC’s Approval of Vimkunya to Prevent Chikungunya
Shots:
- The EC has approved Vimkunya (pre-filled syringe) against CHIKV disease in individuals (≥12yrs.) in 30 EEA states; launch expected in H1’25. MAA under the UK’s MHRA review with decision anticipated in H1’25
- Approval was based on 2 P-III studies that met their 1EP of rapid immune response in 1wk. with ~97.8% of participants (n>3,500) developing neutralizing antibodies by day 21
- Vimkunya is an adjuvanted VLP recombinant protein vaccine with an uncharacterized MoA
Ref: Bavarian Nordic | Image: Bavarian Nordic
Related News:- Bavarian Nordic Receives CHMP’s Positive Opinion for Vimkunya to Prevent Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
